Our findings are supported by Mittag-Roussou et al., whose study included 39 diabetic patients treated with GLP-1 analogs and SGLT-2 inhibitors, having as factors associated with the improvement of hepatic steatosis BMI, CAP, and fasting plasma glucose [35]. This evidence concerns the gene SLC5A2 and Hepatic steatosis.